Hyperoxia-induced changes in human airway epithelial cells: The protective effect of perflubron

Pediatric Critical Care Medicine

Volumn 6, Issue 2, 2005, Pages 188-194

  Babu, Polani B Ramesh ^a   Chidekel, Aaron ^a   Shaffer, Thomas H ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Airway epithelial cells; Apical surface fluid; Calu 3; Hyperoxia; Liquid ventilation; Perflubron; Transepithelial resistance

Indexed keywords

INTERLEUKIN 8; PERFLUOROOCTYL BROMIDE; POLYCARBONATE;

AIR; ARTICLE; CELL COUNT; CELL CULTURE; CELL DAMAGE; CELL GROWTH; CELL PROTECTION; CELL STRUCTURE; CELL SURFACE; CELL VACUOLE; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIUM CELL; FILTER; GAS; HISTOLOGY; HUMAN; HUMAN CELL; HYPEROXIA; IN VITRO STUDY; LABORATORY TEST; LIQUID; LIQUID VENTILATION; LUNG INJURY; MONOLAYER CULTURE; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; PROTEIN SECRETION; RESPIRATORY EPITHELIUM;

CELL CULTURE TECHNIQUES; EPITHELIAL CELLS; FLUOROCARBONS; HUMANS; HYPEROXIA; INTERLEUKIN-8; LIQUID VENTILATION; LUNG; RESPIRATORY INSUFFICIENCY;

EID: 19444369180     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000154944.67042.4F     Document Type: Article

References (53)

1. Greenspan JS, Wolfson MR, Rubenstein SD, et al: Liquid ventilation of human preterm neonates. J Pediatr 1990; 117:106-111
2. Hirschl RB, Pranikoff T, Gauger P, et al: Liquid ventilation in adults, children, and full-term neonates. Lancet 1995; 346: 1201-1202
3. Leach CL, Greenspan JS, Rubenstein SD, et al: Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group. N Engl J Med 1996; 335:761-767
4. Greenspan JS, Fox WW, Rubenstein SD, et al: Partial liquid ventilation in critically ill infants receiving extracorporeal life support. Philadelphia Liquid Ventilation Consortium. Pediatrics 1997; 99:E2
5. Gauger PG, Pranikoff T, Schreiner RJ, et al: Initial experience with partial liquid ventilation in pediatric patients with the acute respiratory distress syndrome. Crit Care Med 1996; 24:16-22
6. Hirschl RB, Pranikoff T, Wise C, et al: Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA 1996; 275:383-389
7. Davies M: Liquid ventilation. J Paediatr Child Health 1999; 35:434-437
8. Day SE, Gedeit RG: Liquid ventilation. Clin Perinatol 1998; 25:711-722
9. Weis CM, Fox WW: Current status of liquid ventilation. Curr Opin Pediatr 1999; 11: 126-132
10. Smith TM, Steinhorn DM, Thusu K, et al: A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages. Crit Care Med 1995; 23:1533-1539
11. Steinhorn DM, Papo MC, Rotta AT, et al: Liquid ventilation attenuates pulmonary oxidative damage. J Crit Care 1999; 14:20-28
12. Rotta AT, Gunnarsson B, Hernan LJ, et al: Partial liquid ventilation with perflubron attenuates in vivo oxidative damage to proteins and lipids. Crit Care Med 2000; 28:202-208
13. Wispe JR, Roberts RJ: Molecular basis of pulmonary oxygen toxicity. Clin Perinatol 1987; 14:651-666
14. Jenkinson SG: Oxygen toxicity. New Horiz 1993; 1:504-511
15. Fukuzawa K, Kishikawa K, Tadokoro T, et al: The effects of alpha-tocopherol on site-specific lipid peroxidation induced by iron in charged micelles. Arch Biochem Biophys 1988; 260:153-160
16. Rotta AT, Gunnarsson B, Fuhrman BP, et al: Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and non-biological systems. Pediatr Crit Care Med 2003; 4:233-238
17. Lane T, Smith D, Wancewicz E, et al: Inhibition of endotoxin-mediated activation of endothelial cells by a perfluorocarbon emulsion. Biomater Artif Cells Immobilization Biotechnol 1993; 21:163-172
18. Rotta AT, Steinhorn DM: Partial liquid ventilation reduces pulmonary neutrophil accumulation in an experimental model of systemic endotoxemia and acute lung injury. Crit Care Med 1998; 26:1707-1715
19. Rotta AT, Gunnarsson B, Hernan LJ, et al: Partial liquid ventilation influences pulmonary histopathology in an animal model of acute lung injury. J Crit Care 1999; 14:84-92
20. Hirschl RB, Tooley R, Parent AC, et al: Improvement of gas exchange, pulmonary function, and lung injury with partial liquid ventilation. A study model in a setting of severe respiratory failure. Chest 1995; 108:500-508
21. Bruch LA, Flint A, Hirschl RB: Pulmonary pathology of patients treated with partial liquid ventilation. Mod Pathol 1997; 10: 463-468
22. Baba A, Kim YK, Zhang H, et al: Perfluorocarbon blocks tumor necrosis factor-alpha-induced interleukin-8 release from alveolar epithelial cells in vitro. Crit Care Med 2000; 28:1113-1118
23. Wolfson MR, Greenspan JS, Deoras KS, et al: Comparison of gas and liquid ventilation: Clinical, physiological, and histological correlates. J Appl Physiol 1992; 72:1024-1031
24. Overbeck MC, Pranikoff T, Yadao CM, et al: Efficacy of perfluorocarbon partial liquid ventilation in a large animal model of acute respiratory failure. Crit Care Med 1996; 24: 1208-1214
25. Hirschl RB, Croce M, Gore D, et al: Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 165:781-787
26. Foster KA, Avery ML, Yazdanian M, et al: Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm 2000; 208:1-11
27. Zhang Y, Reenstra WW, Chidekel A: Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: Pharmacologic alteration by corticosteroids and beta(2)-agonists. Am J Respir Cell Mol Biol 2001; 25:196-202
28. Borchard G, Cassara ML, Roemele PE, et al: Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sci 2002; 91:1561-1567
29. Cowley EA, Linsdell P: Oxidant stress stimulates anion secretion from the human airway epithelial cell line Calu-3: implications for cystic fibrosis lung disease. J Physiol 2002; 543:201-209
30. Babu R, Zhang Y, Reenstra WW, et al: Detection of secretory IgA and lysozyme in apical surface washings of human airway cell line Calu-3: Lack of effect of clinical agents. Pediatr Pulmonol 2001; S22:278
31. Babu R, Chidekel A, Shaffer T: Alteration of antibacterial properties of human airway cell line Calu-3: Effect of ion transport mediators. Pediatr Pulmonol 2002; S24:278
32. Babu R, Chidekel A, Shaffer TH: Protein composition of apical surface fluid from the human airway cell line Calu-3: Effect of ion transport mediators. Clin Chim Acta 2004; 347:81-88
33. Babu R, Chidekel A, Utidjian L, et al: Regulation of apical surface fluid and protein secretion in human airway epithelial cell line Calu-3. Biochem Biophys Res Commun 2004; 319:1132-1137
34. Smith J, Travis S, Greenberg P, et al: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229-236
35. Travis S, Conway B, Zabner J, et al: Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999; 20: 872-879
36. Bals R, Weiner D, Wilson J: The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999; 103:303-307
37. Donnelly S, Strieter R, Kunkel S: Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993; 341:643-647
38. Chollet-Martin S, Montravers P, Gibert C, et al: High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect Immun 1993; 61:4553-4559
39. Bonfield T, Konstan M, Berger M: Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104:72-78
40. Foster KA, Oster CG, Mayer MM, et al: Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998; 243:359-366
41. Kazzaz JA, Xu J, Palaia TA, et al: Cellular oxygen toxicity. Oxidant injury without apoptosis. J Biol Chem 1996; 271:15182-15186
42. Wong HR, Menendez IY, Ryan MA, et al: Increased expression of heat shock protein-70 protects A549 cells against hyperoxia. Am J Physiol 1998; 275:L836-841
43. Allen CB, White CW: Glucose modulates cell death due to normobaric hyperoxia by maintaining cellular ATP. Am J Physiol 1998; 274: L159-164
44. Kazzaz JA, Horowitz S, Li Y, et al: Hyperoxia in cell culture. A non-apoptotic programmed cell death. Ann N Y Acad Sci 1999; 887: 164-170
45. Standiford TJ, Kunkel SL, Basha MA III, et al: Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest 1990; 86:1945-1953
46. Smart SJ, Casale TB: Pulmonary epithelial cells facilitate TNF-alpha-induced neutrophil chemotaxis. A role for cytokine networking. ]J Immunol 1994; 152:4087-4094
47. Kwon OJ, Au BT, Collins PD, et al: Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am J Physiol 1994; 267: L398-405
48. Nakstad B, Wolfson MR, Shaffer TH, et al: Perfluorochemical liquids modulate cell-mediated inflammatory responses. Crit Care Med 2001; 29:1731-1737
49. Shaffer TH, Wolfson MR, Greenspan JS, et al: Liquid ventilation in premature lambs: Uptake, biodistribution and elimination of perfluorodecalin liquid. Reprod Fertil Dev 1996; 8:409-416
50. Barry BE, Geyer RP, Brain JD: Pulmonary effects of blood replacement with a perfluorochemical emulsion followed by exposure to 85% oxygen or air. Am Rev Respir Dis 1988; 138:435-444
51. Patel MM, Szanto P, Yates B, et al: Survival and histopathologic changes in lungs of hamsters following synthetic liquid breathing. Fed Proc 1970; 29:1740-1745
52. Mrozek JD, Smith KM, Bing DR, et al: Exogenous surfactant and partial liquid ventilation: Physiologic and pathologic effects. Am J Respir Crit Care Med 1997; 156:1058-1065
53. Steinhorn DM: Surfactant production is maintained during partial liquid ventilation. Pediatr Res. 1994; 35:60A